Objectives The objectives of this study were to determine if ABCB1 polymorphisms are associated with interindividual variability in sitagliptin pharmacokinetics and if atorvastatin alters the pharmacokinetic disposition of sitagliptin in healthy volunteers.
Introduction
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that is used in the treatment of type 2 diabetes [1] [2] [3] . It undergoes little hepatic metabolism, and about 80 % of the drug is excreted unchanged in the urine, mainly through active tubular secretion [2, 4, 5] . In vitro and clinical data suggest that sitagliptin is a substrate for the efflux transporter, Pglycoprotein (P-gp) [6, 7] , which is expressed on the brush border membrane of intestinal enterocytes and the luminal side of renal proximal tubular cells [8] . It can be hypothesized that interindividual variability in P-gp-mediated transport of sitagliptin, as a result of genetic polymorphisms or drug-drug interactions, may contribute to alterations in sitagliptin pharmacokinetics in humans.
The most commonly studied polymorphisms in ABCB1, the gene that encodes P-gp, are c.1236C>T (rs1128503), c.2677G>T/A (rs2032582), and c.3435C/T (rs1045642), and these polymorphisms are often evaluated in haplotype form (i.e., 1236/2677/3435) [9] . In vitro, ABCB1 3435T, in combination with 1236T and/or 2677T, has been associated with changes in P-gp conformation and decreased P-gp function [10] . ABCB1 3435T has also been shown to affect mRNA stability [11] . In vivo, there are conflicting reports regarding the association between ABCB1 genetics and drug exposure for different P-gp substrates [9, 12] . To our knowledge, the extent to which common ABCB1 single nucleotide polymorphisms affect sitagliptin pharmacokinetics has not been studied.
Atorvastatin, an HMG-CoA reductase inhibitor (statin), is used to lower cholesterol and reduce the risk of cardiovascular disease in patients with type 2 diabetes [13] [14] [15] [16] [17] [18] [19] . In vitro data show that atorvastatin is both a substrate and an inhibitor of Pgp [20] [21] [22] [23] [24] [25] [26] [27] . In clinical studies, atorvastatin has been shown to alter the pharmacokinetics of the P-gp substrates digoxin and aliskiren [21, 28] . Sitagliptin and atorvastatin are frequently co-administered in patients with type 2 diabetes; however, a pharmacokinetic assessment of the effect of atorvastatin on sitagliptin disposition has not been conducted in humans.
Given the gaps in knowledge regarding the impact of ABCB1 genetics and P-gp-mediated drug-drug interactions on sitagliptin disposition, the objectives of our study were to: (1) determine if ABCB1 polymorphisms are associated with interindividual variability in sitagliptin pharmacokinetics and (2) determine if atorvastatin alters sitagliptin pharmacokinetics in healthy volunteers.
Materials and methods

Study design
The investigation was conducted as an open-label, randomized, two-phase crossover study in healthy volunteers prospectively stratified according to ABCB1 diplotype. In one phase, participants received a single 100 mg dose of sitagliptin by mouth at 8:00 a.m. In the other phase, participants received 40 mg of atorvastatin by mouth at 8:00 a.m. for 5 days, with a single 100 mg dose of sitagliptin administered by mouth at 8:00 a.m. on day 5. A 14-day washout period separated the two phases. After each sitagliptin dose, an intensive 24-h pharmacokinetic study was conducted at the University of Colorado Clinical and Translational Research Center. Participants started the pharmacokinetic studies in the fasted state, and a standardized breakfast (600 calories; 55 % carbohydrates, 15 % protein, and 30 % fat) was administered 2 h after sitagliptin dosing. Warm meals were also given 6, 10, and 24 h after sitagliptin administration. Participants abstained from caffeine and smoking during the 24-h period. Blood samples (5 ml in EDTA) were collected pre-dose and 0. 5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20 , and 24 h post-dosing in both phases. Plasma was harvested within 30 min and stored at −80°C until analytical processing. Urine, which was kept on ice, was collected from 0 to 12 h and 12 to 24 h. The volume of urine collected during each 12-h period was recorded. A 10-ml urine aliquot was removed and stored at −80°C until analytical processing. Blood glucose was measured by finger-stick at 1, 2, 3, and 4 h after sitagliptin administration to assess for hypoglycemia.
Study participants
Healthy men and women between 21 and 60 years of age were recruited to participate in the study, which was approved by the Colorado Multiple Institutional Review Board. All subjects provided written informed consent. Participants were prospectively screened and stratified according to ABCB1 (1236/2677/3435) diplotype as follows: Group 1, CGC/CGC (reference); Group 2, CGC/TTT; Group 3, TTT/TTT.
For inclusion in the study, metabolic, renal, hepatic, and hematologic laboratory parameters had to be within normal limits. Participants were excluded for any of the following: current or past history of cardiovascular, hepatic, renal, endocrine, gastrointestinal, pulmonary, hematologic, immunologic, or neurologic diseases. Other pertinent exclusion criteria were: body mass index of <18 kg/m 2 or >30 kg/m 2 , body weight of <50 kg, creatinine clearance of <60 ml/min based on the Cockcroft-Gault formula, lipid-lowering therapy (e.g., statins), inhibitors or inducers of P-gp or cytochrome P450 (CYP) 3A4, and/or medications known to affect drug absorption (e.g., cholestyramine).
Genetic analyses
For genetic screening, a buccal cell sample was collected via a mouthwash method [29] . Genomic DNA was isolated using a QIAamp DNA Mini kit (Qiagen, Valencia, CA). The ABCB1 polymorphisms, c.1236C>T (rs1128503), c.2677G>T/A (rs2032582), and c.3435C>T (rs1045642), were genotyped by PCR-pyrosequencing (PSQ 96MA; Qiagen). ABCB1 haplotypes and diplotypes were computationally assigned using HelixTree Genetics Analysis software (Golden Helix, Bozeman, MT).
Drug concentration analyses
Plasma and urine concentrations of sitagliptin and plasma concentrations of atorvastatin and its metabolites (i.e., atorvastatin lactone, 4-hydroxyatorvastatin, 4-hydroxyatorvastatin lactone, 2-hydroxyatorvastatin, and 2-hydroxyatorvastatin lactone) were measured with a validated liquid chromatography/tandem mass spectrometry assay. The detailed bioanalytical methods are provided in the Electronic Supplementary Material (ESM). The limits of quantification (LOQs) for sitagliptin in plasma and in urine were 0.22 and 0.11 ng/ml, respectively. The LOQs for atorvastatin and its metabolites in plasma were: atorvastatin, 0.60 ng/ml; atorvastatin lactone, 0.31 ng/ml; 4-hydroxyatorvastatin, 0.30 ng/ml; 4-hydroxyatorvastatin lactone, 0.29 ng/ml; 2-hydroxyatorvastatin, 0.60 ng/ml; 2-hydroxyatorvastatin lactone, 0.62 ng/ml. The betweenday coefficient of variation (CV) for plasma sitagliptin was 12 % for low concentration quality controls, and <10 % for medium and high concentration quality controls. For plasma atorvastatin and its metabolites, the between-day CVs for low concentration quality controls were 13 % (atorvastatin) and <20 % (atorvastatin metabolites). The CVs for medium and high concentration quality controls were <16 % for atorvastatin and its metabolites.
Pharmacokinetic analyses
Plasma concentration-time curves of sitagliptin, atorvastatin (acid), atorvastatin lactone, and atorvastatin metabolites were generated and the maximum plasma concentration (C max ) and time to reach C max (T max ) were taken from the curves. Pharmacokinetic parameters were estimated using noncompartmental methods with WinNonlin ver. 5.2.1 software (Pharsight Corp, Mountain View, CA). The terminal elimination rate constant (λ z ) was obtained by regression of the log-linear portion of the curves. Sitagliptin area under the plasma concentration-time curve from 0 to infinity (AUC 0−∞ ) and from 0 to 24 h (AUC 0−24 ), and the AUC for atorvastatin acid, atorvastatin lactone, and atorvastatin metabolites over the dosing interval (AUC tau ) were calculated using the linear-log trapezoidal rule. Half-lives (t 1/2 ) were calculated as 0.693 divided by λ z . For the calculation of sitagliptin renal clearance (CL R ), the amount of sitagliptin collected over each 12-h period was multiplied by the urine volume collected during that period, and the two amounts were summed. The fraction of sitagliptin excreted unchanged in the urine (f e ) was calculated as the total amount of sitagliptin excreted during the 24-h period divided by dose. CL R was determined as the product of f e and CL/F.
Statistical analyses
Baseline demographics were compared between ABCB1 1236/2677/3435 diplotype groups using Fisher exact tests for categorical variables and one-way analysis of variance (ANOVA) for continuous variables. Pharmacokinetic parameters that did not follow a normal distribution were logtransformed for statistical analysis and then back-transformed for data presentation. For the assessment of the potential interaction between sitagliptin and atorvastatin, sitagliptin pharmacokinetic parameters were presented as 90 % confidence intervals (CI) surrounding the geometric mean ratios (GMRs). The 90 % CIs were compared to the pre-specified no-effect bounds of 0.8-1.25. If the 90 % CI of sitagliptin AUC 0−∞ fell entirely within the pre-specified bounds, it was concluded that atorvastatin did not have a clinically significant effect on sitagliptin exposure [30] . Pharmacokinetic data were compared within each ABCB1 diplotype group using paired t tests or Wilcoxon signed rank tests (for time data). Pharmacokinetic data, including relative changes, were compared between ABCB1 diplotype groups using one-way ANOVA, KruskalWallis tests (for time data), or generalized linear model analysis (for assessment of covariates). An a priori power calculation is provided in the ESM. Statistical analyses were conducted using SPSS ver. 18.0 software (SPSS, Chicago, IL). A P value <0.05 was considered to be statistically significant.
Results
We prospectively screened 145 subjects for ABCB1 1236/2677/3435 diplotypes, and 33 subjects started the study protocol. Four subjects participated in only one phase of the study-two withdrew for personal reasons and two were During the sitagliptin monotherapy phase, there was modest variability in sitagliptin C max , AUC 0−∞ , and AUC 0 −24 , with a CV% of 37, 33, and 32 %, respectively. In terms of ABCB1 genetics, the pharmacokinetics of sitagliptin (when administered alone) did not differ significantly between CGC/CGC, CGC/TTT, and TTT/TTT diplotype groups (Table 2) . Sitagliptin CL R and f e were numerically greater in the TTT/TTT group than in the CGC/TTT and CGC/CGC groups; however, these results did not reach statistical significance (P=0.21 and P=0.44, respectively), C max Maximum plasma concentration; T max , time to reach C max ; AUC 0−∞ , AUC 0−24 , area under the plasma time-concentration curve (AUC) from 0 to infinity, and from 0 to 24 h, respectively; CL R , renal clearance; f e , fraction of sitagliptin excreted unchanged in the urine; t 1/2 , half-life Data are expressed as the arithmetic mean± SD, or as the mean relative change, with the 95 % confidence interval (95 % CI) given in parenthesis ABCB1 CGC/CGC, n=9 subjects; ABCB1 CGC/TTT, n=10; ABCB1 TTT/TTT, n=10 a Relative change = (sitagliptin + atorvastatin)/sitagliptin alone even when controlling for creatinine clearance (P=0.36 and P=0.64, respectively). Atorvastatin administration did not significantly affect sitagliptin pharmacokinetics ( Fig. 1; Table 3 ), with 90 % CIs that fell within the pre-specified bounds of 0.8-1.25. Median sitagliptin T max was 3 h in the absence and presence of atorvastatin. ABCB1 diplotype did not influence sitagliptin pharmacokinetics in the presence of atorvastatin (Table 2) . Likewise, mean relative changes in sitagliptin pharmacokinetic parameters did not differ significantly within or between ABCB1 diplotype groups ( Table 2 ). When the analysis was restricted to Caucasians only, there were no significant differences in sitagliptin pharmacokinetic parameters between ABCB1 diplotype groups in the monotherapy phase, in the presence of atorvastatin, or for relative changes (data not shown).
Atorvastatin and atorvastatin lactone pharmacokinetic parameters did not differ significantly between ABCB1 diplotype groups (Table 4) . Along the same lines, the pharmacokinetics of 2-hydroxyatorvastatin, 2-hydroxyatorvastatin lactone, 4-hydroxyatorvastatin, and 4-hydroxyatorvastatin lactone were not significantly affected by ABCB1 diplotype (Table 4) .
Discussion
We sought to determine the impact of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers. Our main finding was that sitagliptin pharmacokinetics did not differ significantly between ABCB1 diplotypes (i.e., CGC/CGC, CGC/TTT, and TTT/TTT). We also found that atorvastatin did not alter the disposition of sitagliptin.
Given in vitro data showing that ABCB1 polymorphisms have putative functional consequences [10, 11, 31, 32] , we hypothesized that the ABCB1 1236T/2677T/3435T haplotype may be associated with increased sitagliptin plasma exposure as a result of decreased renal clearance and/or increased oral bioavailability of sitagliptin. Our findings GMR, Geometric mean ratio a CL R and f e could not be calculated for three subjects due to missing urine samples or incomplete urine collection b Arithmetic mean±SD do not support this hypothesis, as sitagliptin plasma exposure did not differ significantly between the ABCB1 CGC/CGC, CGC/TTT, and TTT/TTT diplotype groups. This does not imply that P-gp does not have a role in sitagliptin disposition, but rather, that ABCB1 CGC/CGC, CGC/TTT, and TTT/TTT diplotypes do not significantly influence sitagliptin pharmacokinetics in vivo. Similar findings have been observed for the P-gp substrate digoxin, with some studies showing that ABCB1 polymorphisms have no impact on digoxin pharmacokinetics [31, 33] . It is well-known that ABCB1 pharmacogenetic studies are influenced by confounding factors (e.g., race, co-medication, genotype vs. haplotype); therefore, the influence of ABCB1 genetics on the disposition of sitagliptin merits study in additional cohorts [31] . In vitro data also indicate that sitagliptin is a substrate for other drug transporters, such as human organic anion transporter 3 (hOAT3) and organic anion transporting polypeptide 4C1 (OATP4C1) [6] . As such, the effect of OAT3 and OATP4C1 gene polymorphisms on sitagliptin disposition warrants investigation in clinical studies. Sitagliptin is commonly co-administered with atorvastatin in clinical practice [19] . Atorvastatin has been shown to significantly increase the plasma concentrations of some P-gp substrates, such as digoxin, aliskiren, and verapamil, in healthy volunteers [21, 28, 34] . We found that sitagliptin pharmacokinetic parameters were unchanged following steady-state administration of atorvastatin. These results are consistent with the fact that atorvastatin is not a potent inhibitor of P-gp in vivo, producing plasma concentrations that are often much lower than its half maximal inhibitory concentration (IC 50 ) [7, 35] . In terms of other, more potent P-gp inhibitors, a healthy volunteer study showed a single 600 mg dose of cyclosporine modestly increased sitagliptin C max , but did not have a significant effect on overall sitagliptin plasma exposure [7] . Taken together, it does not appear that inhibition of P-gp alters sitagliptin disposition to a great extent in humans. Our drug interaction assessment was conducted in the setting of a diplotype enrichment design; therefore, the findings are only applicable to individuals with ABCB1 CGC/CGC, CGC/TTT, or TTT/TTT diplotypes. We also studied a moderate, 40 mg dose of atorvastatin. It remains to be determined whether atorvastatin administration in the setting of other ABCB1 diplotypes, or high-dose (80 mg) atorvastatin, has a clinically meaningful impact on sitagliptin concentrations. This is unlikely given the low frequency and questionable functional significance of other polymorphic ABCB1 diplotypes, the absence of any interaction with the 40 mg dose, and the wide therapeutic index of sitagliptin [2, 7, 36, 37] . Our drug interaction findings are consistent with data showing that statins do not alter the concentrations of other DPP-4 inhibitors (e.g., alogliptin, vildagliptin, saxagliptin) to an appreciable extent [38] . For example, atorvastatin 80 mg and simvastatin 80 mg did not alter the multipledose pharmacokinetics of alogliptin and vildagliptin, respectively, in healthy volunteers [39, 40] . Simvastatin 40 mg increased saxagliptin C max by 21 % and AUC by 12 %; however, the magnitude of this interaction was determined not to be clinically significant [41] . We did not assess the impact of sitagliptin on atorvastatin pharmacokinetics because evidence suggests that sitagliptin does not inhibit or induce CYP3A4 or P-gp [3] . However, a few patient case reports have been published which attribute the development of rhabdomyolysis to the concomitant administration of sitagliptin with various statins (e.g., lovastatin, simvastatin, and atorvastatin) [42] [43] [44] . Healthy volunteer studies do not indicate that DPP-4 inhibitors have a major effect on statin pharmacokinetics; therefore, the mechanisms underlying the observations in these case reports are unclear [38] .
We found no differences in atorvastatin or atorvastatin metabolite disposition between CGC/CGC, CGC/TTT, and TTT/TTT diplotypes [45] . In contrast, a few studies have shown that ABCB1 haplotypes influence atorvastatin pharmacokinetics in healthy volunteers. Keskitalo et al. found that atorvastatin acid, 2-hydroxyatorvastatin, and 4-hydroxyatorvastatin plasma exposures were greater in Caucasian subjects with the TTT/TTT diplotype than in those with the CGC/CGC diplotype [45] . Lee et al. found that atorvastatin, atorvastatin lactone, 2-hydroxyatorvastatin, and 2-hydroxyatorvastatin lactone half-lives, but not plasma exposures, were greater in Korean subjects with two copies of the 2677T/3435T haplotype as compared with those with the GC/GC and GC/TT diplotypes [46] . Unlike these previous studies, we did not investigate SLCO1B1 hepatic uptake transporter polymorphisms, which are known to influence statin pharmacokinetics [47] . Therefore, SLCO1B1 polymorphisms may have confounded our assessment of the influence of ABCB1 polymorphisms on atorvastatin disposition. Other possible reasons for the discrepancies between studies may include different race/ethnic demographics of the study cohorts, small sample size, concomitant medications (e.g., sitagliptin), and failure to consider polymorphisms in other drug metabolizing enzyme and transporter genes (e.g., CYP3A5, ABCG2).
In conclusion, sitagliptin pharmacokinetics did not differ between ABCB1 CGC/CGC, CGC/TTT, and TTT/TTT diplotypes in healthy volunteers. Furthermore, atorvastatin had no effect on the pharmacokinetics of sitagliptin in the setting of this ABCB1 diplotype enrichment study.
